false 0001433607 0001433607 2026-11-20 2026-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): November 20, 2026

 

InspireMD, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35731   26-2123838
(Commission
File Number)
  (IRS Employer
Identification No.)

 

6303 Waterford District Drive, Suite 215
Miami, Florida
  33126
(Address of Principal Executive Offices)   (Zip Code)

 

(888) 776-6804

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   NSPR   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

As previously disclosed, on November 16, 2026, InspireMD, Inc. (the “Company”) closed its previously announced offering of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and pre-funded warrants to purchase up to 50,350,000 shares of Common Stock, and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of Common Stock (the “Common Warrants”), pursuant to the Company’s effective automatic shelf registration statement on Form S-3 (File No. 333-286309) previously filed with the Securities and Exchange Commission (the “SEC”), raising approximately $34.9 million in net proceeds after deducting underwriting discounts and before offering expenses. Pursuant to the Underwriting Agreement, dated November 13, 2026 (the “Underwriting Agreement”), by and among the Company and Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), the Underwriters were granted a 30-day option (the “Option”) to purchase up to an additional 8,635,846 shares of Common Stock (the “Option Shares”) and/or Common Warrants to purchase up to 6,490,384 shares of Common Stock (the “Option Common Warrants”) from the Company on the same terms and conditions.

 

On November 18, 2026, the Representative notified the Company that it had elected to exercise the Option in full. The offering of the Option Shares and Option Common Warrants closed on November 20, 2026, raising an additional approximately $5.3 million in net proceeds after deducting underwriting discounts and before offering expenses.

 

The Option Common Warrants will be issued pursuant to a warrant agency agreement, dated as of November 12, 2026, by and between the Company and Securities Transfer Corporation, as warrant agent.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INSPIREMD, INC.
   
Date: November 20, 2026 By: /s/ Marvin Slosman
  Name: Marvin Slosman
  Title: Chief Executive Officer